A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.

Advances in neurology

Volumn 69, Issue , 1996, Pages 531-534

  Rascol, O ^a   Lees, A J ^a   Senard, J M ^a   Pirtosek, Z ^a   Brefel, C ^a   Montastruc, J L ^a   Fuell, D ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; LEVODOPA; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG POTENTIATION; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; LEVODOPA; MOVEMENT DISORDERS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2;

EID: 0029685213     PISSN: 00913952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)